25

2025

-

07

Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting

Author:

On July 25, 2025, Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting. The meeting was presided over by General Manager Chen Shaoyan, and all members of the company's board of directors and managers at the director level and above attended the meeting. Team leaders were also in attendance.

On July 25, 2025, Hubei Guangchen Pharmaceutical Co., Ltd. held its 2025 first-half work summary meeting. The meeting was chaired by General Manager Chen Shaoyan. All members of the company's board of directors and managers at the supervisory level and above attended the meeting; team leaders were also in attendance.

The meeting heard work summary reports from the heads of various departments, covering four aspects: the completion of major work in the first half of the year, existing problems, improvement measures and suggestions, and talent cultivation. General Manager Chen Shaoyan deployed the key tasks for various departments in the second half of the year, and Chairman Lei Shaoqing made an important exposition on the company's key aspects of operation and management.

Related News

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Linagliptin/metformin extended-release tablets (I), marketed under the brand name LedaTang®, is a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. and held as the marketing authorization holder; it is also the first extended-release formulation of its kind approved for marketing in China.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

LE DA TANG is a pharmaceutical brand dedicated to the treatment of diabetes, with its flagship product being “LE DA TANG® Linagliptin–Metformin Extended-Release Tablets (I).” This combination antidiabetic formulation contains the DPP‑4 inhibitor linagliptin and the biguanide metformin hydrochloride. Manufactured by Hubei Guangchen Pharmaceutical Co., Ltd., it is the first domestically approved extended-release formulation of its kind, indicated for glycemic control in adult patients with type 2 diabetes who are suitable for treatment with both linagliptin and metformin.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Ledar Tang® Linagliptin-Metformin Extended-Release Tablets (I) are the first domestically approved extended-release formulation, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. This product combines the DPP‑4 inhibitor linagliptin with metformin hydrochloride; it is taken once daily, one tablet per dose, with meals, and is indicated, in conjunction with dietary management and exercise, for glycemic control in adult patients with type 2 diabetes who are suitable candidates for treatment with both linagliptin and metformin.

Hubei Guangchen Pharmaceutical Co., Ltd. Has Been Recognized as a Credible Enterprise Abiding by Contracts for the 15th Yichang Session (2024–2025)

2026-08-03